From: FiercePharma

By: Kyle Blankenship

 

 

 

 

 

AbbVie’s Rinvoq Continues March with NICE Nod in Rheumatoid Arthritis

In December, a rheumatologist survey conducted by Spherix Global Insights showed about half of 100 physicians would prescribe Rinvoq over other JAK inhibitors, specifically citing AbbVie’s “stewardship” of the drug as a positive for prescribing, Piper analyst Christopher Raymond said in a note to investors…(read more).